Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03526835 · ClinicalTrials.gov registry record · Phase 1

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

A Phase 1 study of Colorectal Cancer and Gastric Cancer, sponsored by Merus B.V..

Recruiting
Registry status
Phase 1
Development phase
523
Enrollment target
20
Study locations

NCT03526835 is a Phase 1 study of Colorectal Cancer and Gastric Cancer that is actively recruiting participants, run by Merus B.V.. The registered enrollment target is 523 participants, below the 1,510-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03526835, a Phase 1 study of Colorectal Cancer and Gastric Cancer, is actively recruiting participants, sponsored by Merus B.V..

RECRUITING
Registry status
Phase 1
Development phase
523 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansion part of the study. Cohorts of selected solid tumor indications for which there is evidence of EGFR dependency and potential sensitivity to EGFR inhibition will be evaluated including head and neck cancer and metastatic colorectal cancer (mCRC). The study will further assess the safety, tolerability, PK, PD, immunogenicity, and anti-tumor activity of MCLA-158 in monotherapy or in combination with other therapies.

Conditions Studied

Colorectal Cancer Gastric Cancer Esophageal Cancer Head and Neck Squamous Cell Carcinoma NSCLC HNSCC Gastroesophageal-junction Cancer Advanced/Metastatic Solid Tumors

Interventions

  • DRUG MCLA-158
  • COMBINATION_PRODUCT MCLA-158 + Pembrolizumab
  • COMBINATION_PRODUCT MCLA-158 + FOLFIRI
  • COMBINATION_PRODUCT MCLA-158 + FOLFOX

Study Locations (20)

California

  • UCSD - La Jolla
  • USC Norris Comprehensive Cancer Center - Los Angeles
  • Sharp Healthcare - San Diego

Texas

  • Texas Oncology - Dallas
  • Oncology Consultants - Houston
  • Texas Oncology - Tyler

Florida

  • Florida Cancer Specialists - Fort Myers
  • Sarah Cannon Research Institute (Lake Nona) - Orlando

Missouri

  • SSM Health Saint Louis University Hospital - St Louis
  • Washington University School of Medicine at St Louis - St Louis

New York

  • Cayuga Medical Center - Ithaca
  • Hematology-Oncology Associates of Central New York - Syracuse

Ohio

  • Cleveland Clinic - Cleveland
  • Taylor Cancer Research Center - Maumee

Tennessee

  • The University Of Tennessee Health Science Center - Memphis
  • Sarah Cannon Research Institute - Nashville

Colorado

  • Rocky Mountain Cancer Centers - Lone Tree

Trial Details

FieldValue
Enrollment Target 523 participants
Start Date 2018-05-02
Est. Completion 2027-11
Phase Phase 1

Sponsor

Merus B.V.

8 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03526835

The ClinicalTrials.gov registry entry for NCT03526835 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 523 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,510-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (65% lower). The listed sponsor is Merus B.V., which has 8 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 4 interventions - of which MCLA-158 is the first listed.

NCT03526835 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Texas, Florida.

Frequently Asked Questions

What is clinical trial NCT03526835 about?

NCT03526835 is a clinical study titled "A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors". This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been completed and the RP2D will be further evaluated in an expansio...

What is the current status of trial NCT03526835?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 523 participants. The study started on 2018-05-02. Estimated completion is 2027-11.

What conditions does trial NCT03526835 study?

This clinical trial studies the following conditions: Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Head and Neck Squamous Cell Carcinoma, NSCLC.

What interventions are being tested in trial NCT03526835?

The interventions under investigation include: MCLA-158 (DRUG), MCLA-158 + Pembrolizumab (COMBINATION_PRODUCT), MCLA-158 + FOLFIRI (COMBINATION_PRODUCT), MCLA-158 + FOLFOX (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT03526835?

This trial is sponsored by Merus B.V., which has 8 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03526835 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Colorectal Cancer

All registered trials for this condition

Gastric Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.